Percentage of persons with prescribed drugs in 2020 by specialist care*
| Total | None | Rheumatology | Pulmonology | Both | |
| N | 1484 | 321 | 379 | 244 | 540 |
| Age, mean, years (SD) | 72 (10) | 75 (10) | 72 (10) | 71 (10) | 71 (10) |
| 31–50 (%) | 2.4 | 0.9 | 1.6 | 2.5 | 3.9 |
| 51–70 (%) | 39 | 33 | 37 | 45 | 40 |
| >70 (%) | 59 | 66 | 62 | 53 | 56 |
| Female (%) | 69 | 68 | 74 | 65 | 67 |
| Glucocorticoids | 68 | 58 | 70 | 66 | 74 |
| Any csDMARD | 55 | 40 | 64 | 43 | 64 |
| Methotrexate | 33 | 25 | 39 | 23 | 37 |
| Leflunomide | 10 | 5.0 | 14 | 7.8 | 12 |
| HCQ | 8.2 | 5.6 | 7.7 | 4.9 | 12 |
| Mycophenolate | 2.1 | 1.9 | 1.6 | 3.7 | 1.9 |
| Sulfasalazine | 0.5 | 0.0 | 1.3 | 0.4 | 0.2 |
| Any bDMARD | 24 | 13 | 31 | 18 | 29 |
| TNF inhibitor | 11 | 7.8 | 12 | 9.4 | 13 |
| Abatacept | 6 | 2.2 | 6.3 | 3.3 | 8.0 |
| Rituximab | 2.7 | 0.0 | 3.4 | 0.8 | 4.6 |
| Tocilizumab | 3.8 | 1.9 | 6.3 | 3.3 | 3.5 |
| JAK inhibitor | 6.5 | 3.4 | 8.4 | 2.9 | 8.7 |
| NSAIDs | 38 | 34 | 39 | 39 | 39 |
| Analgesics | 44 | 46 | 48 | 41 | 42 |
| Opioids | 30 | 39 | 32 | 21 | 26 |
| Nintedanib | 2.2 | 0.3 | 0.3 | 4.0 | 4.0 |
| Pirfenidone | 0.4 | 0.3 | 0.8 | 0.6 |
*At least one contact to the corresponding specialist in 2020.
cs/bDMARD, conventional synthetic/biological disease-modifying antirheumatic drug; HCQ, hydroxychloroquine; JAK, Janus kinase; NSAIDs, non-steroidal anti-inflammatory drugs; TNF, tumour necrosis factor.